Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

Overview

The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis of cml is being performed within 1 year. Quality of life will be carefully assessed.

Full Title of Study: “Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase With Age More Than 70, Diagnosis of CML is Being Performed Within 1 Year”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

Patients will received Imatinib at a dose of 400mg daily. Tolerability and quality of life will be assessed Secondary objectives are : to evaluate the survival without progression, the survival without event, the overall survival, the hematologic, cytogenetic and molecular responses at various check points. Duration of responses and failure to respond will be evaluated.

Interventions

  • Drug: Imatinib mesylate 400 mg

Clinical Trial Outcome Measures

Primary Measures

  • Tolerability
  • Quality of life

Secondary Measures

  • . the survival without progression
  • . the survival without event
  • . the overall survival
  • . the hematologic cytogenetic and molecular responses at various check points.
  • . duration of responses and failure to respond

Participating in This Clinical Trial

Inclusion Criteria

  • CML Ph+ (assessed by cytogenetic or FISH) – Chronic phase with less than 5% bone marrow blasts – Diagnosis within 12 months – Age ≥ 70 year at inclusion – PS grade 0 to 2 (ECOG) – Mini mental status more than 25 – Hydroxyurea optional before Imatinib – Adequate end organ function, defined as the following: total bilirubin <1.5x uln, sgpt <3x uln, creatinine <1.5x uln. Exclusion Criteria:

  • patients who cannot sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital – Mini mental status ≤ 25 – patients who are not able to adequately take the study drug – Age less than 70 y – accelerated or blastic phase – previous therapy with imatinib or interferon – HIV positivity

Gender Eligibility: All

Minimum Age: 70 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Poitiers University Hospital
  • Collaborator
    • Novartis
  • Overall Official(s)
    • François GUILHOT, MD, Study Chair, Department of Oncology hematology and Cell therapy, University Hospital , 86021 Poitiers – FRANCE
    • Philippe ROUSSELOT, MD, Principal Investigator, Department of Hematology and Oncology – University Hospital “Saint Louis” – 75475 PARIS cedex 10 (FRANCE)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.